您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2015, Vol. 53 ›› Issue (11): 46-49.doi: 10.6040/j.issn.1671-7554.0.2015.531

• 临床医学 • 上一篇    下一篇

阿托伐他汀钙联合依折麦布治疗冠状动脉粥样硬化并高脂血症的临床疗效

容春莉, 姚文静, 杨倩, 李如意, 曹东平, 刘美霞, 彭应心   

  1. 河北省人民医院心脏中心, 河北 石家庄 050051
  • 收稿日期:2015-06-01 出版日期:2015-11-10 发布日期:2015-11-10
  • 通讯作者: 彭应心.E-mail:upls01@163.com E-mail:upls01@163.com
  • 基金资助:
    河北省科技攻关计划项目(03276196D-54)

Clinical efficacy of atorvastatincalcium combined with ezetimibe in the treatment of coronary atherosclerosis with hyperlipidemia

RONG Chunli, YAO Wenjing, YANG Qian, LI Ruyi, CAO Dongping, LIU Meixia, PENG Yingxin   

  1. Center of Heart, Hebei General Hospital, Shijiazhuang 050051, Hebei, China
  • Received:2015-06-01 Online:2015-11-10 Published:2015-11-10

PDF (PC)

289

摘要： 目的 探讨阿托伐他汀钙联合依折麦布治疗冠状动脉粥样硬化并高脂血症患者的临床疗效与安全性.方法 选取2013年5月至2014年2月收治的冠状动脉粥样硬化并高脂血症患者82例,根据就诊顺序随机分为单用组和联用组,每组41例.单用组采用阿托伐他汀钙治疗,20 mg/次,1次/d.联用组在此基础上加用依折麦布,10 mg/次,1次/d.比较两组治疗12周后降脂效果差异.结果 治疗前单用组与联用组总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、C反应蛋白(CRP)值无明显差异(P>0.05),治疗后两组TC、TG、LDL-C、CRP值较治疗前均显著降低,HDL-C显著增高(P<0.05),联用组较单用组变化更加显著(P<0.05).联用组LDL-C达标率(78.05%)显著高于单用组(53.66%)(P<0.05).两组治疗前后肝功能、肾功能指标变化差异无统计学意义(P>0.05).结论 阿托伐他汀钙联合依折麦布治疗冠状动脉粥样硬化并高脂血症的降脂效果更显著,同时不会加重肝肾负担.

关键词: 依折麦布, 冠状动脉粥样硬化, 高脂血症, 阿托伐他汀钙, 降脂效果

Abstract: Objective To investigate the clinical efficiency and safety of atorvastatincalcium combined with ezetimibe for treating coronary atherosclerosis with hyperlipidemia. Methods A total of 82 cases of coronary atherosclerosis with hyperlipidemia treated in our hospital during May 2013 to Feb. 2014 were collected and divided into two groups. Patients in single drug group (n=41) were treated with atorvastatincalcium only, while patients in the combined drug group (n=41) received atorvastatincalcium and ezetimibe. After 12 weeks, lipid contents of the two groups were compared. Results Before the treatment, the values of TC, TG, HDL-C, LDL-C, and CRP in the two groups were not significantly different (P>0.05). After the treatment, the values of TC, TG, LDL-C, CRP in the two groups were markedly reduced and HDL-C was remarkably increased than before (P<0.05), and the improvement was greater in the combined drug group (P<0.05). The standard rate of LDL-C was 78.05% in combined drug group, which was notably higher than that of the single drug group (53.66%) (P<0.05). There were no differences in liver and renal function between the two groups before and after treatment (P>0.05). Conclusion Atorvastatincalcium combined with ezetimibe has significant lipid-lowering effect in treating coronary atherosclerosis with hyperlipidemia, and does not increase the burden on liver and kidney.

Key words: Coronary atherosclerosis, Hyperlipidemia, Atorvastatincalcium, Ezetimibe, Lipid-lowering effect

中图分类号: 

  • R574
[1] Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis[J]. Lancet, 2010, 375(9709): 132-140.
[2] Cleeman JI. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adults treatment panel III)[J]. JAMA, 2001, 285(19): 2486-2497.
[3] 中国成人血脂异常防治指南制定联合委员会. 中国成人血脂异常防治指南[J]. 中华心血管病杂志, 2007, 35(5): 390-419. Joint committee for developing Chinese guidelines on prevention and treatment of dyslipidemia in adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults[J]. Chinese Journal of Cardiology, 2007, 35(5):390-419.
[4] Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvascular outcomes in coronary heart disease patients with baseline elevations in alanine aminotransferase levels[J]. Eur Heart J, 2013, 34(1): 679-683.
[5] 李毅亭, 龙明智. 强化他汀治疗对急性冠脉综合征患者炎症因子和预后的影响[J]. 南京医科大学学报: 自然科学版, 2009, 10: 1423-1426. LI Yiting, LONG Mingzhi. Effects of intensive statin therapy on inflammatory factors and prognosis in patients with acute coronary syndrome[J]. Acta Universitatis Medicinalis Nanjing:Natural Science, 2009, 10: 1423-1426.
[6] Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J]. N Engl J Med, 2004, 350(15): 1495-1504.
[7] 王艳丽, 于晓原, 张璐璐, 等. 阿托伐他汀钙治疗老年冠心病合并高脂血症的疗效观察[J]. 西北药学杂志, 2013, 1(6) :630-631. WANG Yanli, YU Xiaoyuan, ZHANG Lulu, et al. Clinical effect of atorvastatin calcium in the treatment of elder patients with coronary heart disease complicated with hyperlipidemia[J]. Northwest Pharmaceutical Journal, 2013, 1(6): 630-631.
[8] Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome[J]. N Engl J Med, 2012, 366(1): 9-19.
[9] 陈莉, 王勇. 稳定型冠心病患者的强化他汀治疗[J]. 中国全科医学, 2012, 15(14): 1557-1559. CHEN Li, WANG Yong. Intensive statin therapy in patients with stable coronary artery disease[J]. Chinese General Practice, 2012, 15(14): 1557-1559.
[10] 王一楠. 阿托伐他汀联合非诺贝特治疗老年混合型高脂血症临床疗效观察[J]. 中国心血管病研究, 2011, 9(10): 765-768.
[11] Bays HE, Neff D, Tomassini JE, et al. Ezetimibe: cholesterol lowing and beyond[J]. Expert Rev Cardiovasc Ther, 2008, 6(4): 447-470.
[12] 张茗, 任祝军, 赵丽芬,等. 依折麦布联合小剂量普伐他汀治疗高胆固醇血症疗效观察[J]. 河北医药, 2013, 35(15): 2301-2302.
[13] 童程程, 唐海沁, 李瑾. 依折麦布联合辛伐他汀降脂疗效和安全性的Meta分析[J]. 中国循证心血管医学杂志, 2013, 5(2): 116-120. TONG Chengcheng, TANG Haiqin, LI Jin. A Meta-analysis on lipid-lowering effect and safety of ezetimibe combining simvatatin therapy[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2013, 5(2): 116-120.
[14] Dujovne CA, Ettinger MP, McNeer JF, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia[J]. Am J Cardiol, 2002, 90(10): 1092-1097.
[15] 毕磊, 曹丹阳, 王伟, 等. 依折麦布联合辛伐他汀在冠心病高脂血症患者中降脂疗效及安全性观察[J]. 中国循证心血管医学杂志, 2014, 6(4): 422-423. BI Lei, CAO Danyang, WANG Wei, et al. Lipid-lowering efficacy and safety of ezetimibe combining simvastatin in patients with coronary heart disease and hyperlipidemia[J]. Chinese Journal of Evidence-Based Cardiovascular Medicine, 2014, 6(4): 422-423.
[1] 张光,王广银,吴红彦, 张红玉,王停停,李吉庆,李敏,康凤玲,刘言训,薛付忠. 健康管理人群高脂血症风险预测模型[J]. 山东大学学报（医学版）, 2017, 55(6): 72-76.
[2] 刘艳君，巩会平，杜贻萌，王欣，董兆强，鹿庆华. 人端粒保护蛋白1与冠状动脉病变的关系[J]. 山东大学学报(医学版), 2013, 51(10): 58-61.
[3] 张敏1，2，徐贵发1. 单纯高脂血症患者非药物干预的疗效评价[J]. 山东大学学报(医学版), 2010, 48(8): 117-119.
[4] 徐明明1，易咏红1，张萌2. 轻度认知功能障碍与ApoE基因多态性及血脂水平的研究[J]. 山东大学学报(医学版), 2009, 47(11): 103-107.
[5] 吴茂红,王奉云,孙磊,董明,任建民 . 2型糖尿病患者餐后高脂血症与颈动脉粥样硬化病变及纤溶活性关系的研究[J]. 山东大学学报(医学版), 2007, 45(5): 503-507.
[6] 刘相菊,高海青,毕轶,沈琳,由倍安. 阿托伐他汀联合葡萄籽原花青素预防兔动脉硬化的研究[J]. 山东大学学报(医学版), 2007, 45(11): 1131-1134.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发